OnCore moving fast toward IPO

In the wake of two deals to acquire HBV assets, OnCore Biopharma Inc. (Doylestown, Pa.) on Monday said it had submitted draft registration materials to SEC for a proposed IPO.

OnCore was founded in 2012 by former Pharmasset Inc. executives, including one credited with inventing HCV blockbuster Sovaldi sofosbuvir before the biotech was acquired by Gilead Sciences Inc. (NASDAQ:GILD). The company has said it intends to create the first oral HBV cure and plans to bring multiple combination therapies to clinic next year (see BioCentury Extra, Oct. 1). ...